Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study.

Julie C BlantNicola N De RossiRalf Gold Aude MauroussetMarkus KraemerLucía Romero-PinelTatsuro Misu Jean-Christophe OualletMaud Pallix GuyotSimonetta GereviniChristos BakirtzisRaquel Piñar Morales Benjamin Vlad Panajotis Karypidis Xavier Moisset Tobias J Derfuss Ilijas JelcicGuillaume Martin-BlondelIlya Ayzenberg Corey Mcgraw David-Axel LaplaudRenaud A Du PasquierRenaud A Du Pasquiernull null

Published in: Neurology(R) neuroimmunology & neuroinflammation (2024)

S1P-RM-associated PML shows reduced IRIS risk but higher post-treatment MS activity. Clinicians should tailor post-PML treatment based on pre-PML medication.

Keyphrases

multiple sclerosis
palliative care
clinical trial
ms ms
cross sectional
case report
drug induced